Skip to main content
OpenTrials
Completed

NCT Number: NCT05476575

The Effect of Perioperative Hydrogen Inhalation on Post-operative Pain and Inflammation Cytokines

To understand the impact of perioperative hydrogen inhalation on post-operative pain control and serum inflammation markers

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fu Jen Catholic University Hospital

New Taipei City, 24300, Taiwan

About this study

Hydrogen is odorless, colorless gas existing in natural environment. It was traditionally thought as biologically inert gas, which means it does not participate in biological process. However, recent studies have demonstrated that ingestion of hydrogen have exerted therapeutic effect on skin squamous cell carcinoma and parasitic hepatitis. Ingestion of hydrogen could also attenuate ischemic-reperfusion injury after stroke by removing reactive oxygen species (ROS). Multiple studies also demonstrated that ingestion of hydrogen exhibit anti-inflammatory effect, leading to less post-operative cognitive impairment, lung graft injury in brain-dead mice and acute lung injury.

Means of hydrogen ingestion include oral, inhalation or intravenous injection. Inhalation through simple mask, nasal cannula or ventilator is most convenient way. It has been proved that low concentration of hydrogen inhalation (1%-4%) is effective and safe without causing adverse effects on hemodynamic, respiration or even data of arterial blood gas analysis. High concentration of hydrogen inhalation is proven to be harmless and is often used in diving, treating decompression sickness and preventing arterio-venous thromboembolism.

Current data suggests that microglial cells in dorsal root ganglion are activated by danger-associated molecular pattern (DAMP) through toll-like receptor response (TLR) after external insults. Lipopolysaccharides (LPS) are recognized as TLR-4 receptor agonist and data revealed that LPS is associated with significant neuroinflammation and chronic pain process. Peripheral blood monocyte cells(PBSC) could have pro- (e.g. Tumor necrosis factor-α(TNF-α)、Interleukin-6(IL-6)、Interferon-γ(INF-γ) ) and anti- inflammation (e.g. IL-4、IL-5、IL-9、IL-10) cytokines release after LPS stimulation.

Current data suggests that hydrogen-rich water ingestion could reduce inflammation and pain score in animal model. Hydrogen inhalation is associated with decrease of pro-inflammation cytokines, such as IL-1β, IL-6, TNF-α and INF-γ. Besides, hydrogen inhalation could lead to reduction of pain in rats with high level spinal cord injury.

In addition to observing the difference of pain score between groups, we could also observe the differences between pro- and anti- inflammation cytokines in PBSC after LPS stimulation in patients receiving or not receiving hydrogen inhalation. This could tell us whether the inflammation process is inhibited in cellular level by hydrogen inhalation. To our knowledge, there is no human clinical trials discussing the effect of hydrogen inhalation on chronic pain. We hope to understand the actual impact of hydrogen inhalation on post-operative pain score and inflammation. Further larger scale randomized clinical trials could be carried on based on this result.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with herniated disc leading to severe neuropathic pain refractory to conservative treatment, receiving endoscopic discectomy.

Exclusion criteria

  • American Society of Anesthesiologists class IV or above
  • Sever impairment of heart, lung, kidney and liver and autoimmune disease
  • Less than 20 years old or older than 75 years old
  • Patient refusal
  • Severe complication occurring perioperatively
  • Current pregnancy
  • Hemoglobin less than 10g/dL.

Treatment and study plan

hydrogen inhalation, 4% concentration, given via nasal cannula

Other

4% hydrogen inhalation via nasal cannula perioperatively

Primary outcomes

  1. Post-operative pain

    Time frame: immediately post-operative compared to pre-operative pain score measured in VAS

    Post-operative pain, measured in visual analogue scale (VAS)

  2. Post-operative pain

    Time frame: 12 hours after operation compared to pre-operative pain score measured in VAS

    Post-operative pain, measured in visual analogue scale (VAS)

  3. Post-operative pain

    Time frame: 24 hours after operation compared to pre-operative pain score measured in VAS

    Post-operative pain, measured in visual analogue scale (VAS)

  4. Post-operative pain

    Time frame: 1 week after operation compared to pre-operative pain score measured in VAS

    Post-operative pain, measured in visual analogue scale (VAS)

  5. Post-operative pain

    Time frame: 1 month after operation compared to pre-operative pain score measured in VAS

    Post-operative pain, measured in visual analogue scale (VAS)

Secondary outcomes

  1. Inflammation marker, Interleukin-6

    Time frame: immediate post-operation compared to pre-operation

    Interleukin-6

  2. Inflammation marker, Interleukin-10

    Time frame: immediate post-operation compared to pre-operation

    Interleukin-10

  3. Inflammation marker, Tumor necrotic factor-alpha

    Time frame: immediate post-operation compared to pre-operation

    Tumor necrotic factor-alpha

  4. Inflammation marker, Interleukin-1 beta

    Time frame: immediate post-operation compared to pre-operation

    Interleukin-1 beta

Sponsors and collaborators

Lead sponsor

Fu Jen Catholic University Hospital

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jul 27, 2022
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.